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Abstract
Aims/Objectives: Extensive research considers associations between inpatient glycaemic control and outcomes during
hospital admission; this cautions against overly tight glycaemic targets. Little research considers glycaemic control following
hospital discharge. This is despite a clear understanding that people with diabetes are at increased risk of negative
outcomes, following discharge. We evaluate absolute and relative Hba1c values, and frequency of Hba1c monitoring, on
readmission and mortality rates for people discharged from hospital with diabetes.
Methods: All discharges (n¼ 46,357) with diabetes from a major tertiary referral centre over 3 years were extracted,
including biochemistry data. We conducted an evaluation of association between Hba1c, mortality and readmission,
statistical significance and standardised Cohen’s D effect size calculations.
Results: 399 patients had a Hba1c performed during their admission. 3,138 patients had a Hba1c within 1 year of discharge.
Mean average Hba1c for readmissions was 57.82 vs 60.39 for not readmitted (p¼ 0.009, Cohen’s D 0.28). Mean average
number of days to Hba1c testing in readmitted was 97 vs 113 for those not readmitted (p¼ 0.00006, Cohen’s D 0.39). Further
evaluation of mortality outcomes, cohorts of T1DM and T2DM and association of relative change in Hba1c was performed.
Conclusions: Lower Hba1c values following discharge from hospital are significantly associated with increased risk of
readmission, as is a shorter duration until testing. Similar patterns observed for mortality. Findings particularly prominent
for T1DM. Further research needed to consider underlying causation and design of appropriate risk stratification models.
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Introduction
Diabetes represents a condition of impaired glycaemic
control.1 Therefore, one of the central features of dia-
betes care aims to return glycaemic control into a phys-
iological range through diet, oral medications or
injectable medications.2,3 Glycaemic control is typically
measured through either fingerpick blood sugar read-
ings or glycosylated haemoglobin levels (Hba1c).4 The
glycosylated haemoglobin value (Hba1c) reports the
amount of glucose bound to haemoglobin molecules,
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and represents an average of blood sugar control over
the preceding 6weeks prior to the test being taken.4
There are not “normal values” for Hba1c as such,
however the Hba1c value can be used in both the
diagnosis of T2DM and monitoring of all types diabe-
tes (although less useful in monitoring gestational dia-
betes mellitus – GDM. When monitoring control of
diabetes, using Hba1c, it is typically the change in
Hba1c value over time that is most useful rather than
an individual Hba1c value. NICE generally recom-
mend an Hba1c level target of 48mmol/mol in treat-
ment of T2DM. However, they stress that this target
must be personalised and should be relaxed to
53mmol/mol, where there is a risk of hypoglycaemia.
There is good evidence that maintaining glycaemic
levels within physiological levels can reduce or mini-
mise the risk of diabetic complications, in the long
term (months-years), both for patients with type 1 dia-
betes and type 2 diabetes.5,6 Shorter term blood sugar
control can also have a significant impact on health
outcomes, with significantly higher or lower readings
resulting in significant morbidity, mortality and health-
care utilisation.
Managing glycaemic control in the context of inter-
current illness and diabetes is, a relatively complex pro-
cess. In particular, there has been significant research
considering the optimal glycaemic control for patients
who are inpatients within hospital settings. There is a
need to balance the risks of overly tight glycaemic con-
trol that risks hypoglycaemia versus the risks of throm-
bosis, diabetic ketoacidosis and hyperosmolar
hyperglycaemic state that can occur with higher
blood sugar values. It has been identified that glycae-
mic control can impact on both survival and length of
stay for people with diabetes admitted to hospital.7
Hyperglycaemia has clearly been associated with
adverse patient outcomes across a number of studies.8,9
However, interventions that have aimed to correct
blood sugars into normal ranges have either not
improved outcomes10,11 or in certain circumstances
have led to worsening outcomes.11 Randomised con-
trolled trials have suggested that hypoglycaemia is the
primary driver of worsening patient outcomes associ-
ated with overly intense inpatient blood sugar con-
trol.12 Therefore, the overall consensus and guideline
driven position for inpatient glycaemic control is that
in general inpatient populations, a moderate, rather
than overly tight control is advisable to optimise
patient outcomes, including length of stay and readmis-
sion risk.13
However, when considering the impact of glycaemic
control on the discharge process from hospital, and
associated risks of readmission or mortality there has
been much less research. Four articles consider the
impact of glycaemic control in general on readmission;
one of which focuses on the importance of the “most
extreme blood sugar value” during inpatient admission
and the second article considers the impact of glycae-
mic variability. These articles, therefore, considered rel-
atively specific markers of inpatient glycaemic control
and both were restricted to specific subsets of hospital
inpatients with diabetes.14–17 The Diabetes Early Re-
admission Risk Indicator (DERRI) is an externally val-
idated and important tool that aims to predict all cause
readmission within 30 days for patients discharged
from hospital with diabetes, and found Hba1c to be
significantly associated with readmission,18 the paper
however notes that adding HbA1c to DERRI did not
increase the accuracy of the model.
Importantly, however, there has been considerably
more research looking at the impact of inpatient hypo-
glycaemia on readmission patterns for patients dis-
charged from hospital with diabetes.19–23 These
studies all considered generalised populations of
people with diabetes admitted to hospital, rather than
specific subsets of patients. It is likely that this focus on
hypoglycaemia and readmission patterns is driven by
an awareness of hypoglycaemia as a major driver of
hospital admission and, therefore, cost in diabetes
management. Remarkably, there is even less research
considering the impact of glycaemic control on mortal-
ity outcomes following hospital discharge.
This paper looks to perform the first evaluation of
the impact of glycaemic control on discharge outcomes
of mortality and readmission, when patients with dia-
betes are discharged from hospital. It focuses on both
the value of glycosylated haemoglobin and the frequen-
cy of monitoring. The use of Hba1c is selected due to
its ready availability in electronic health record sys-
tems. As such it facilitates an informatics-based
approach both in this research, but also when consid-
ering wider dissemination and adoption of this work in
other settings.
Methods
The study adopted a retrospective evaluation of data
extracted from the electronic health record (EHR) of a
large tertiary referral centre, in the West Midlands
region of the United Kingdom, for all patients dis-
charged from University Hospitals Coventry and
Warwickshire NHS Trust with a diagnosis of diabetes,
over a 3-year period. Only adult patients with Type 1
or Type 2 diabetes were included. Patients with GDM
were excluded from the study. This is because Hba1c
values vary significantly during pregnancy, with no
clear normal ranges established.24 Indeed, the
National Institute of Health & Clinical Excellence do
not recommend Hba1c measurement during
pregnancy.25
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All Hba1c values for patients in the region (includ-
ing those performed in the community setting) are ana-
lysed at the hospital laboratory and included within the
electronic health record. Hba1c values were extracted
for all patients discharged with diabetes as above.
Patients from outside the region may have had Hba1c
values calculated at other hospital laboratories and
whose readings would not appear on University
Hospital Coventry & Warwickshire NHS Trusts
Electronic Health Record. Therefore, patients, who
had postcode sectors outside of the Coventry &
Warwickshire region, were also excluded from the
study. Extraction of data was supported by a
Biochemistry Performance and Programme
Management Office Analyst.
The outcomes of interest were readmission within
30 days and mortality within 365 days. Multiple dis-
charges were included per patient if they were admitted
more than once. The association between Hba1c abso-
lute values and frequency of Hba1c monitoring was
analysed using Student’s T-Test, following adequate
assessment for skew and kurtosis to ensure normality.
An absolute skew value larger than 2 or an absolute
kurtosis (proper) larger than 7 may be used as reference
value for determining substantial non-normality. A
p-value of <0.05 was considered significant.
Standardised size was evaluated using Cohen’s D for
pre-specified patient cohorts of patients with Type 1
Diabetes and Patients with Type 2 diabetes.
Ethical approval was granted by the local NHS
Trust Research Ethics Committee, at University
Hospitals Coventry & Warwickshire NHS Trust
through the Governance arrangements for Research
Ethics Committee Process [Study Ref: GF0220].
Approval was also granted through the University of
Warwick’s Biomedical & Scientific Research Ethics
Committee [Study Ref: REGO-2017-2114].
All statistical testing was performed using Microsoft
Excel 201626 and IBM’s SPSS v24.27
Results
Hba1c during admission
There were 399 patients meeting the inclusion criteria
described above, who had a Hba1c sample analysed
and recorded in the electronic health record system,
during their hospital admission prior to discharge. 52
of these patients were readmitted within 30 days and 63
died within 365 days. The mean average Hba1c value of
this cohort overall was 73mmol/mol.
Hba1c during admission – Readmission (Table 1)
The mean average Hba1c, during admission for
patients, who were not readmitted within 30 days,
was 74.6mmol/mol, compared to 65.6mmol/mol for
patients readmitted within 30 days of discharge
(p¼ 0.006, Cohen’s D 0.33).
Hba1c during admission – Mortality (Table 2)
The mean average Hba1c, assessed during admission for
patients who survived 365days, was 69.05mmol/mol
Table 1. Association of Hba1c during admission with readmission (generalised population of patients with diabetes).
Average Hba1c during admission n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 309 74.58 1.10 1.29
Readmitted within 30 days 52 65.62 1.78 3.98
P-value 0.0058
Cohen’s D 0.33
Table 2. Association of Hba1c during admission with mortality (generalised population of patients with diabetes).
Average Hba1c during admission n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 305 69.05 0.99 0.75
Died within 365 days 56 64.11 2.19 6.37
P-value 0.10
Cohen’s D 0.21
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and the mean average Hba1c, for patients who died
within 365 days, was 64.11mmol/mol. (p¼ 0.1,
Cohen’s D N/A).
Hba1c post discharge
For patients, who had an Hba1c assessed within a year
of hospital discharge, the mean average Hba1c was
59.9mmol/mol, with an average time until Hba1c
assessment of 110 days.
Hba1c post discharge readmission
When considering absolute Hba1c values and readmis-
sion for generalised populations of patients with diabe-
tes (n¼ 3,403), the average Hba1c value of those not
readmitted to hospital within 30 days was 60.4mmol/
mol, whereas the average Hba1c of those readmitted to
hospital was 57.8mmol/mol (p¼ 0.008, Cohen’s D
0.28) (Table 3).
The average number of days to Hba1c testing, for
those discharged from hospital and not readmitted,
was 115.23, whereas the average number of days until
testing for those discharged and then readmitted was
83.05 days. (p< 0.001, Cohen’s D 0.39) (Table 4).
For patients with type 1 diabetes, the average Hba1c
for those not readmitted was 74.4mmol/mol, whereas
the average Hba1c for those readmitted was
63.6mmol/mol (p¼ 0.0077, Cohen’s D 0.44) (Table 5).
The average number of days, between hospital dis-
charge and the Hba1c being tested, was 109.4 for those
readmitted and 114.9 for those not readmitted
(p¼ 0.72, Cohen’s D N/A) (Table 6).
For patients with type 2 diabetes, the average Hba1c
for those not readmitted was 58.8mmol/mol, whereas
the average Hba1c for those readmitted was
57.5mmol/mol (p¼ 0.19, Cohen’s D N/A) (Table 7).
The average number of days, between discharge and
Hba1c being tested for those not readmitted, was
Table 3. Association of Hba1c post-discharge with readmission (generalised population of patients with diabetes).
Average Hba1c post-discharge (All) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 2618 60.39 1.50 3.60
Readmitted within 30 days 520 57.82 1.75 4.15
P-value 0.0088
Cohen’s D 0.28
Table 4. Association between readmission and time to testing Hba1c (generalised population of people with diabetes).
Average time to hba1c post-discharge (All) N Average No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 2618 115.23 0.80 –0.18
No. of days test , readmission within 30d 520 83.05 1.01 0.34
P-value 0.00006
Cohen’s D 0.39
Table 5. Association of Hba1c post-discharge with readmission (T1DM population).
Average Hba1c post-discharge (T1DM) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 281 74.37 1.39 4.13




113.5 days, compared to 95.2 days for those readmitted
(p< 0.001, Cohen’s D 0.33) (Table 8).
Hba1c post discharge mortality
The average Hba1c for the generalised population of
patients with diabetes, who were discharged and
survived for over one year, was 60.2mmol/mol, where-
as the average Hba1c for those with mortality within
1 year was 56.7mmol/mol (p¼ 0.007, Cohen’s D 0.18)
(Table 9).
The mean average time to Hba1c testing, for those
who survived over a year, was 112 days, whereas the
mean average time to testing, for those with mortality
Table 6. Association between readmission and time to testing Hba1c (T1DM).
Average time to hba1c post-discharge (T1DM) N Average No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 281 109.46 0.89 –0.21
No. of days to test, readmission within 30d 42 114.86 0.76 –0.54
P-value 0.72
Cohen’s D N/A
Table 7. Association of Hba1c post-discharge with readmission (T2DM population).
Average Hba1c post-discharge (T2DM) n Av Hba1c (mmol/mol) Skew Kurtosis
Not readmitted within 30 days 2246 58.83 1.45 2.59
Readmitted within 30 days 459 57.50 1.88 4.95
P-value 0.19
Cohen’s D N/A
Table 8. Association between readmission and time to testing Hba1c (T2DM).
Average time to hba1c post-discharge (T2DM) n No. of days Skew Kurtosis
No. of days to test, no readmission within 30d 2246 113.50 0.80 –0.23
No. of days to test, readmission within 30d 459 95.23 1.05 0.50
P-value 0.00002
Cohen’s D 0.33
Table 9. Association of Hba1c post-discharge with mortality (generalised population of patients with diabetes.
Average Hba1c post-discharge (All) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 2924 60.206 1.54 3.57
Died within 365 days 214 56.73 1.28 1.97
P-value 0.0074
Cohen’s D 0.18
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within 1 year, was 83 days (p< 0.001, Cohen’s D 0.37)
(Table 10).
For patients with type 1 diabetes, the average Hba1c
for those who survived to 365 days, post discharge, was
73.2mmol/mol, whereas the average Hba1c for those
readmitted was 59.4mmol/mol (p< 0.001, Cohen’s D
0.78) (Table 11).
The average number of days, between hospital dis-
charge and the Hba1c being tested, was 110.8 for those
readmitted and 98.5 for those not readmitted (p¼ 0.59,
Cohen’s D N/A) (Table 12).
For patients with type 2 diabetes, the average
Hba1c, for those who survived 365 days post discharge,
was 58.3, whereas the average Hba1c for those who
died within 365 days was 54.2 (p¼ 0.07, Cohen’s D
N/A) (Table 13).
The average number of days between discharge and
Hba1c being tested, for those not readmitted, was
113.5 days, compared to 96.119 days for those readmit-
ted (p< 0.001) Cohen’s D 0.21) (Table 14).
Discussion
The measurement of Hba1c, in patients with diabetes,
has been a mainstay of monitoring disease and the
long-term future risk of microvascular and microvas-
cular risk since the Diabetes Control and
Complications Trial (DCCT) and UK Prospective
Diabetes Study: clinical and therapeutic implications
for type 2 diabetes (UKPDS) published their results.5,28
In both these studies, increased Hba1c values are asso-
ciated with higher levels of adverse outcomes within the
Table 10. Association between mortality and time to testing Hba1c (generalised population of people with diabetes).
Average time to hba1c post-discharge n No. of days Skew Kurtosis
No. of days to test, survived 365 days 2924 112.19 0.81 –0.21
No. of days to test, died within 365 days 214 83.33 1.17 0.93
P-value <0.0001
Cohen’s D 0.36
Table 11. Association of Hba1c post-discharge with mortality (T1DM population).
Average Hba1c post-discharge (T1DM) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 308 73.20 1.27 3.58
Died within 365 days 15 59.41 –0.26 –1.57
P-value 0.00023
Cohen’s D 0.78
Table 12. Association between mortality and time to testing Hba1c (T1DM).
Average time to hba1c post-discharge (T1DM) n No. of days Skew Kurtosis
No. of days to test, survived 365 days 308 110.89 0.87 –0.26




patient populations. The research, reported in this
paper, represents the first evaluation of the association,
between glycaemic control on discharge outcomes of
mortality and readmission, when patients with diabetes
are discharged from hospital.
The results demonstrated no statistically significant
associations between the Hba1c values, recorded
during the inpatient stay, for both readmission and
mortality outcomes. It is important to note that the
population size was relatively small (361 patients) for
each and may, thus, contribute towards the results not
reaching significance. This small population size is
notable, in that it potentially reflects a large proportion
of patients with diabetes attending hospital but not
having their Hba1c assessed during the admission
period. This does not necessarily mean that clinical
teams were not conscious of the Hba1c measure,
when seeing these patients, but they may have consid-
ered the most recent Hba1c previously collected in the
community setting. Additionally, the Hba1c values typ-
ically take, the laboratory at UHCW, 24 hours to pro-
cess, therefore this delay may mean clinical teams feel
there is less need to request an Hba1c value, for short
admission patients.
However, statistically significant associations were
noted in relation to Hba1c values following discharge
from hospital. The Hba1c value is statistically signifi-
cantly associated with 30-day readmission and 365-day
mortality, in generalised populations of patients with
diabetes. The Hba1c is statistically significantly associ-
ated with readmission and mortality for T1DM cohorts
but this was not seen for T2DM cohorts. Importantly,
for both the generalised population of patients with
diabetes and the T1DM cohorts, it was a higher
Hba1c that was associated with lower rates of mortality
and readmission. This may seem counterintuitive; how-
ever, similar patterns were seen in inpatient studies,
based on finger-prick based glucose readings. In these
studies, higher blood sugar readings were protective.29
This was explained by the high risks of negative out-
comes associated with hypoglycaemia, resulting from
overly tight glycaemic control. It is likely that similar
patterns may be being observed here, with hypoglycae-
mia already known to be a major driver of hospital
readmission30 and mortality.31 It is possible that
T2DM patients, who are on insulin or gliclazide, and
T1DM (who are all on insulin) are the drivers of the
results observed here, for both the generalised popula-
tion of patients with diabetes and T1DM cohort. The
high number of T2DM patients, who are not on hypo-
glycaemia inducing medications, may explain the lack
of significance in this subpopulation. The medications
patients are on is not extractable from the electronic
patient record system used at UHCW NHS Trust and
the source of data for this study. However, this is
potentially and important observation and focus of
future work, UHCW is in the process of procuring a
new EHR system that includes electronic prescribing
components and would facilitate future further work
in this area.
The time, between discharge and the next testing of
Hba1c values, was statistically significantly associated
Table 14. Association between mortality and time to testing Hba1c (T2DM).
Average time to hba1c post-discharge (T2DM) n No. of days Skew Kurtosis
No. of days to test, survived 365 days 2513 113.53 0.80 –0.18
No. of days to test, died within 365 days 192 96.1 1.01 0.34
P-value <0.0001
Cohen’s D 0.21
Table 13. Association of Hba1c post-discharge with mortality (T2DM population).
Average Hba1c post-discharge (T2DM) n Av Hba1c (mmol/mol) Skew Kurtosis
No death within 365 days 2513 58.30 1.54 3.08
Died within 365 days 192 54.18 1.31 2.01
P-value 0.07
Cohen’s D N/A
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with both readmission and mortality, for generalised
populations of patients with diabetes. The time,
between discharge and testing, was not significantly
associated with mortality or readmission for patients
with T1DM; however, it was significantly associated
with patients with T2DM. The pattern for the general-
ised diabetes cohort and T2DM cohort follows what
would be anticipated, with negative outcomes associat-
ed with a shorter period to Hba1c measurement. This
likely represents more frequent contact with medical
team for patients with diabetes, who are more likely
to experience negative outcomes, and these medical
teams requesting Hba1c more frequently. The lack of
statistically significant association for patients with
T1DM may be explained either by the smaller sample
size, or perhaps, more likely, by the more frequent con-
tact these populations have with medical teams as a
routine part of their care, regardless of their underlying
risks. Indeed, nearly all T1DM are seen in secondary
care hospital clinics, as opposed to T2DM cohorts who
are managed in the community and, although meant to
have an at least annual nurse review with Hba1c, they
have significantly less contact with medical teams.
This study has a number of limitations. There is the
potential for missing values and missing data. The
number of Hba1c tests, performed during the inpatient
admission period, is perhaps lower than expected.
However, the extraction process was supported by a
Biochemistry Analyst at a University Tertiary Centre
and, therefore, likely reflects a full and complete data-
set, as contained within the clinical system. Any
informatics-based study risks issues with data availabil-
ity and missing values and it would be important to
repeat this study at other centres, in order to look for
differences in the outcomes generated. The analysis of
HbA1c values obtained within 1 year post discharge in
relation to readmission at 30 days may include a sub-
stantial proportion of Hba1c values that were obtained
after the readmission and are therefore not suited to
developing risk prediction models, but do provide
important information regarding the relationship
between Hba1c and patient readmission risk. We did
not consider Hba1c values recorded in the time period
prior to admission to hospital, this could represent
important future work, not only would it allow for
increased sample sizes if this work was to be completed
at a multicentre setting, but it would also enable early
identification of patients at risk of readmission. For
example, if the Hba1c value within the 3months prior
to admission was indeed a risk factor for readmission,
active interventions could be planned throughout the
admission period to reduce future risk.
Secondly, Hba1c values themselves can, to some
extent be unreliable, primarily influenced by factors
affecting the lifespan of a patient’s erythrocytes.32
Whilst, for the vast majority of patients being dis-
charged from hospital, they are likely to represent a
good marker of recent glycaemic control, in some
circumstances, they can be misleading. Reasons for
non-representative Hba1c values can include; blood
transfusions,33 pregnancy,24 sickle cell disease,34 medi-
cations35 and dialysis.36 The most important of these
perhaps being the impact of blood transfusions in
patients discharged following surgery, trauma or gas-
trointestinal bleeding where large volumes of blood
may have been transfused.
This informatics work is exploratory in nature. It is
important to note that we have not adjusted for mul-
tiple observations (through processes such as general-
ized estimating equations), therefore there is a
possibility that associations could be overestimated.
Despite the exploratory nature of the work, it is never-
theless important in demonstrating that biochemistry
data may have an important role in understanding
risk for patients with diabetes. This is also highly rele-
vant, as new technologies may allow earlier identifica-
tion of patterns that have been suggested by the Hba1c
results collected here. Hba1c retrospectively looks at
glucose patterns over the previous 6-week period,
acting as an average effect rather than simple “point-
in-time” blood sugar readings, which are entirely
dependent on when the blood sugar reading is actually
performed (in hospital for example the majority of fin-
gerpick testing may be done around acute decompen-
sations or surgical interventions, during the inpatient
procedure, thus giving a non-representative summary
of the overall blood sugar profile). We are however now
able to gain a better understanding of average blood
sugar readings through continuous blood sugar moni-
toring systems (CGM)37 or interstitial fluid blood sugar
monitoring systems, such as the Freestyle Libre.38 Data
from these systems are not widely available, in relation
to inpatient care and the immediate post discharge
period. However, the research presented here suggests
that such information may be of significant importance
in better understanding the risks, when patients with
diabetes are discharged from hospital.
Finally, this work stresses that the hospital discharge
process is a continuum, not just a point in time, with
Hba1c values stretching across that continuum. This is
a particularly important observation and something
that clinicians often forget.
Conclusion
Glycaemic control is currently the main indicator of
effective diabetes management; typically, this is
assessed through Hba1c values. This paper creates
new knowledge in demonstrating the association
between glycaemic control in the post discharge
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period and negative outcomes of readmission and mor-
tality both for generalised and specific subpopulations
of diabetes. Importantly, this research extends current
understanding from glycaemic control in the inpatient
setting, where low Hba1c values may be associated
with worse outcomes following hospital discharge, par-
ticularly for cohorts of patients with T1DM. This
research represents an exploratory informatics-based
work, identifying the need for further research to char-
acterise the “peri-discharge” period from a glycaemic
perspective. Newer technologies may enable a more
detailed understanding of how glycaemic control
varies, around the time of hospital discharge, and its
subsequent influence on patient outcomes and thus
could form the foundation of important future high-
impact research.
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